Live
- Has Allu Arjun's ‘Pushpa 2’ raked in Rs. 1000 Crore Pre-Release Business?
- Reports of spat with Netanyahu misleading: Germany
- 5.0-magnitude quake hits Alaska Peninsula
- AP assembly elections: Filing of nominations in full swing in the state
- Alaya F stuns in denim look, exudes boss babe energy
- Brillare Clinic Celebrates First Anniversary with Gratitude and Glamour
- Tillu Square: Sidhu Jonnalagadda’s Film to Stream on Netflix in 5 Languages
- Sharwanand’s ‘Maname’ teaser: A glimpse into a refreshing tale
- Hyderabad: ‘SSMB 29’ pre-production underway; team spotted at airport
- LG raises $800 million bond for R&D & facility investments
40 pharma firms showed interest in anti-Covid drug, DRDO in Madras High Court
Madras High Court (Photo/IANS)
The Defense Research and Development Organisation (DRDO) on Friday told the Madras High Court that 40 pharmaceutical companies have evinced interest in the anti-Covid-19 drug produced by it.
Chennai: The Defense Research and Development Organisation (DRDO) on Friday told the Madras High Court that 40 pharmaceutical companies have evinced interest in the anti-Covid-19 drug produced by it.
The submission came in response to a Public Interest Litigation complaining that DRDO had given a license to Dr Reddy's Laboratories in Hyderabad for the production of the anti-Covid-19 drug.
The premier scientific organisation said that it has invited Expressions of Interest (EoIs) to produce its D-glucose (2-DG) and adjunct drug to treat Covid patients, and already 40 pharmaceutical companies had expressed interest.
Additional Solicitor General R. Sankaranarayanan told a bench of Justices N. Kirubakaran and T.V. Thamilselvi that the DRDO was interested in ensuring that the drug, developed by its Institute of Nuclear Medicine and Allied Sciences, could be manufactured in as many quantity as possible in the shortest possible time.
The PIL filed by Chennai resident, D. Saravanan, complained that the DRDO had given license to Dr Reddy's Laboratories in Hyderabad alone for making the oral powder at a cost of Rs 990 for a sachet of 2.34 grams.
The court also took note of a submission made by a litigant that the DRDO's medicine was very effective and a woman Covid-19 patient with comorbidities had a magical cure after being administered with 30 sachets of the drug at a cost of Rs 30,000. The litigant said that the doctor who had treated the patient had said that he can vouch for its efficiency.
Sankaranarayanan told the court that that the DRDO had fixed June 17 as the last date for submission of EoIs and that 40 pharmaceutical companies had envisaged interest to manufacture the medicine with the DRDO knowhow.
The judges reserved their verdict and directed the ASG to circulate all documents related to the case.
